Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v9-EN | Version v7-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2022-06-03 | 2022-06-02 |
| Drug Identification Number | 02172739 | 02172739 |
| Brand name | OMNIPAQUE 240 | OMNIPAQUE 240 |
| Common or Proper name | iohexol injection USP | iohexol injection USP |
| Company Name | GE HEALTHCARE CANADA INC | GE HEALTHCARE CANADA INC |
| Ingredients | IOHEXOL | IOHEXOL |
| Strength(s) | 518MG | 518MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVASCULAR SUBARACHNOIDAL INTRAVASCULAR SUBARACHNOIDAL | INTRAVASCULAR SUBARACHNOIDAL INTRAVASCULAR SUBARACHNOIDAL |
| Packaging size | 200 mL | 200 mL |
| ATC code | V08AB | V08AB |
| ATC description | X-RAY CONTRAST MEDIA, IODINATED | X-RAY CONTRAST MEDIA, IODINATED |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2022-06-14 | 2022-06-14 |
| Actual start date | 2022-06-02 | 2022-06-02 |
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Covid Related Shutdown in China. This is a fluid situation that we are working through daily. We will keep all customers informed on what orders to expect during this period so they can plan accordingly. | Covid Related Shutdown in China. This is a fluid situation that we are working through daily. We will keep all customers informed on what orders to expect during this period so they can plan accordingly. |
| Health Canada comments |